Today, the American Lung Association published its 2024 "State of Lung Cancer" report, highlighting the varying impact of lung cancer across different states. According to the report, Arkansas ranks poorly in terms of lung cancer survival rates, with only 22.6 percent compared to the national average of 28.4 percent. The state also has one of the highest smoking rates in the nation.
Despite these figures, there is a positive trend nationwide. The lung cancer survival rate has improved by 26 percent over the past five years due to better awareness and advancements in detection and treatment methods.
The report outlines opportunities for Arkansas to improve its lung cancer outcomes by increasing access to early screening and biomarker testing. "Lung cancer is a devastating disease and impacts far too many families in Arkansas," said Laura Turner, director of advocacy for Arkansas at the American Lung Association. She emphasized that focusing on increased access to screenings and cessation programs could save lives.
For the first time this year, the report examines health insurance coverage requirements for comprehensive biomarker testing across the U.S., which helps tailor treatment options based on tumor DNA changes. While some health plans in Arkansas require coverage for such testing, it is not universal.
The American Lung Association encourages other states to adopt policies requiring insurance coverage for comprehensive biomarker testing and calls on Congress to pass H.R. 4286—the Increasing Access to Lung Cancer Screening Act.
Additionally, maintaining Medicaid expansion funding is crucial as it supports screening and treatment services essential for lung cancer patients. The association plans to advocate for this during legislative sessions. In rural areas where transportation can be a barrier to accessing care, efforts will focus on improving transport options.
COVID-19 impacted cancer surveillance in Arkansas during 2021; thus certain data are unavailable.
